Evidence map›Paper›PMID 34045552›Full record

ArticleScientific reports2021

Exome sequencing of early-onset patients supports genetic heterogeneity in colorectal cancer.

C Fernández-Rozadilla, M Álvarez-Barona, I Quintana, A López-Novo, J Amigo, J M Cameselle-Teijeiro, E Roman, D Gonzalez, X Llor, L Bujanda and 9 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023
    Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 2 countries.

C Fernández-Rozadilla *Grupo de Medicina Xenómica (USC), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain.
M Álvarez-Barona *Grupo de Medicina Xenómica (USC), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain.
I QuintanaHereditary Cancer Program, Catalan Institute of Oncology, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Barcelona, Spain.
A López-NovoGrupo de Medicina Xenómica (USC), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain.
J AmigoFundación Publica Galega de Medicina Xenómica, SERGAS, Grupo de Medicina Xenomica-USC, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain.
J M Cameselle-TeijeiroServicio de Anatomía Patológica, USC, Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico Universitario, Santiago de Compostela, Spain.
E RomanGastroenterology Department Hospital de Sant Pau, CIBERehd, Escola Universitària D'Infermeria EUI-Sant Pau, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
D GonzalezPatología Digestiva, Hospital de Sant Pau, Barcelona, Spain.
X LlorDepartment of Medicine and Cancer Center, Yale University, New Haven, USA.
L BujandaHospital Universitario de Donostia, Instituto Biodonostia, Universidad del Pais Vasco (UPV/EHU), CIBEREHD, San Sebastián, Spain.
X BessaGastroenterology Department, Hospital del Mar, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
R JoverServicio de Medicina Digestiva, Instituto de Investigación Biomédica (ISABIAL), Hospital General Universitario de Alicante, Alicante, Spain.
F BalaguerGastroenterology Department, Institut D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas Y Digestivas (CIBEREHD), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
A CastellsGastroenterology Department, Institut D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas Y Digestivas (CIBEREHD), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
S Castellví-BelGastroenterology Department, Institut D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas Y Digestivas (CIBEREHD), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
G CapelláHereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
A CarracedoFundación Publica Galega de Medicina Xenómica, SERGAS, Grupo de Medicina Xenómica-USC, Instituto de Investigación Sanitaria de Santiago (IDIS), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Santiago de Compostela, Spain.
L ValleHereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Clara Ruiz-PonteFundación Publica Galega de Medicina Xenómica, SERGAS, Grupo de Medicina Xenómica-USC, Instituto de Investigación Sanitaria de Santiago (IDIS), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Santiago de Compostela, Spain. clara.ruiz.ponte@usc.es.
Instituto de Investigación Sanitaria de Santiago · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESFundación Pública Galega de Medicina Xenómica · ESInstitut d'Investigació Biomédica de Bellvitge · ESCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESHospital Del Mar · ESHospital de Sant Pau · ESHospital General Universitario de Alicante Doctor Balmis · ESInstitut Català d'Oncologia · ESUniversitat Autònoma de Barcelona · ESUniversity of the Basque Country · ESYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is a complex disease that can be caused by a spectrum of genetic variants ranging from low to high penetrance changes, that interact with the environment to determine which individuals will develop the disease. In this study, we sequenced 20 early-onset CRC patients to discover novel genetic variants that could be linked to the prompt disease development. Eight genes, CHAD, CHD1L, ERCC6, IGTB7, PTPN13, SPATA20, TDG and TGS1, were selected and re-sequenced in a further 304 early onset CRC patients to search for rare, high-impact variants. Although we found a recurring truncating variant in the TDG gene shared by two independent patients, the results obtained did not help consolidate any of the candidates as promising CRC predisposing genes. However, we found that potential risk alleles in our extended list of candidate variants have a tendency to appear at higher numbers in younger cases. This supports the idea that CRC onset may be oligogenic in nature and may show molecular heterogeneity. Further, larger and robust studies are thus needed to unravel the genetics behind early-onset CRC development, coupled with novel functional analyses and omic approaches that may offer complementary insight.

Indexed as

ExomeGene Expression Regulation, NeoplasticGenetic HeterogeneityGenetic Predisposition to DiseaseAdultColorectal NeoplasmsDNA-Binding ProteinsDNA HelicasesDNA Repair EnzymesExome SequencingFemaleHumansMaleMethyltransferasesMiddle AgedPoly-ADP-Ribose Binding ProteinsCHD1L protein, humanDNA-Binding ProteinsDNA HelicasesDNA Repair EnzymesERCC6 protein, humanMethyltransferasesPoly-ADP-Ribose Binding ProteinsProtein Tyrosine Phosphatase, Non-Receptor Type 13PTPN13 protein, humantrimethylguanosine synthase

Identifiers

PMID34045552
PMCPMC8159954
OpenAlexW3165701406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.